# Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

> **NCT05078047** · PHASE3 · RECRUITING · sponsor: **UNICANCER** · enrollment: 646 (estimated)

## Conditions studied

- Lung Cancer Metastatic
- Renal Cell Carcinoma
- Head and Neck Cancer
- Triple Negative Breast Cancer
- Merkel Cell Carcinoma
- Hepatocellular Carcinoma
- Melanoma
- Urothelial Carcinoma
- Colorectal Carcinoma With Microsatellite Instability
- Esophageal Squamous Cell Carcinoma
- Endometrial Carcinoma
- Cervical Cancer
- Gastric/Gastro-esophageal Junction/Esophageal Adenocarcinoma
- Basal Cell Carcinoma
- Squamous Skin Carcinoma

## Interventions

- **DRUG:** Reduced dose intensity of IO

## Key facts

- **NCT ID:** NCT05078047
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-08
- **Primary completion:** 2027-03-07
- **Final completion:** 2027-03-07
- **Target enrollment:** 646 (ESTIMATED)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05078047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05078047, "Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05078047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*